EGFR and non-small cell lung carcinoma: In this real‐world LungBEAM study, almost 62% of stage IV NSCLC patients with EGFR sensitizing mutations that received first‐ and second‐generation TKI treatment as first‐line therapy had a PFS event during the 72‐week follow‐up period, with 27.9% of patients showing an emergent plasma p.T790 M mutation detected using BEAMing at some points during the follow‐up.